Executive Director, Chief of Staff, Global Development Operations

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits.

This is work that transforms the lives of patients, and the careers of those who do it.

Serves as the Chief of Staff and strategic thought partner to the Head of Global Development Operations (GDO), with accountability for shaping strategy, driving the GDO transformation agenda, and ensuring disciplined operational execution across the global organization. GDO owns the delivery of the BMS portfolio — predictably, with quality, through an agile, AI-enabled, and integrated global development organization. This role goes beyond coordination to actively define priorities, challenge thinking, and guide decision‑making across GDO's global footprint.

Translates GDO and Drug Development strategy into clear, actionable plans, ensures alignment across therapeutic areas, countries, and functions, and drives execution with a focus on delivery, quality, risk, and impact. Works with and is accountable to the GDO Leadership Team (GDO LT) to define priorities, establish work plans, and drive work streams supporting the five shifts underway: pooled resources to embedded therapeutic area depth;

broad presence to an optimized country footprint; scattered ownership to enterprise quality; manual process to AI-enabled delivery; and internal focus to patient and site orientation. Partners closely with Global Trial Management and Trial Leadership, Transformation & Innovation Operations, Quality and Compliance, and cross‑functional stakeholders to ensure strategic clarity, operational rigor, and end‑to‑end visibility across the delivery continuum.

• Shape Strategy & Direction – Act as a trusted advisor and thought partner to the GDO Head and the GDO LT; help shape strategy, priorities, and key decisions; drive development of the GDO strategy and roadmap, annual objectives, and enterprise alignment (Drug Development LT, BMS LT, Board of Directors as needed)
• Identify delivery risks, trade‑offs, and opportunities across the portfolio and global footprint, and proactively frame strategic options.
• Lead Delivery Insight & Prioritization – Provide end‑to‑end visibility across the delivery continuum, from study start‑up through close‑out, for early and late development. Establish a single source of truth from the frontline to leadership, with consistent delivery metrics on timelines, enrollment, quality, and cost. Assess delivery status, risks, and systemic challenges to execution across therapeutic areas and countries.
• Lead and facilitate prioritization and resource allocation in partnership with Portfolio Strategy Implementation and Reporting (PSI&R), Development Finance, and Business Insights and Analytics; ensure alignment of country enrollment and footprint decisions with enterprise strategy, resourcing, and long‑range financial plans.
• Translate Strategy into Execution – Convert strategic priorities into integrated, actionable plans across GDO functions, therapeutic areas, and regions; drive execution of the GDO transformation roadmap, including the move of Global Trial Managers and Global Trial Leaders into therapeutic area–aligned teams, build‑out of TA depth in Tier 1 countries, and stand‑up of the centralized risk, compliance, and trial enablement Center of Excellence.
• Partner with Transformation & Innovation Operations to…